NASDAQ$ROIV
Roivant Sciences Ltd · Q2 2026 earnings
Q2 2026 earnings · · Before market open · Investor relations
Briefing
Roivant Sciences reported its Q2 2026 results, posting a net loss with lower revenues and higher R&D investment, while highlighting significant clinical progress.
Roivant Sciences faced a challenging quarter with increased R&D expenses and a narrowed net loss. Revenue declined compared to the previous year, but strong pipeline momentum, particularly for brepocitinib and Immunovant’s programs, provided optimism.
- Reported net loss of $113.5 million for the quarter
- Revenue declined to $1.57 million from $4.48 million in Q2 FY25
- R&D expenses rose due to expanded program and headcount
- Strong Phase 3 results for brepocitinib in dermatomyositis with NDA filing planned for 1H 2026
Headline financials
Revenue & EPS history
Roivant Sciences · Revenue · Quarterly
$1.57M
Forward guidance
Roivant expects major clinical and regulatory milestones across its subsidiaries in 2026 and 2027, including NDA filings and multiple topline data readouts.
Tailwinds
- Brepocitinib NDA filing in dermatomyositis expected in 1H 2026
- Phase 3 data in non-infectious uveitis due in 1H 2027
- Proof-of-concept trial readout in cutaneous sarcoidosis in 2H 2026
- Immunovant expected to report TED Phase 3 results in 1H 2026
- Strong cash position of $4.4 billion to support operations into profitability
Headwinds
- Revenue remained minimal and declined year-over-year
- Continued operating losses and high R&D spending
- High G&A expenses, albeit reduced from prior year
- No material revenue contribution from core pipeline assets yet
- Litigation proceedings ongoing, adding potential risk exposure
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2026
+3.3%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.4%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+22.1%
Q3 2026
Best reaction
-5.5%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +14.9% | — | — | |
| Q3 2026 | +22.1% | +26.8% | +36.1% | |
| Q2 2026 | +2.6% | -1.6% | -1.8% | |
| Q1 2026 | -2.8% | +3.1% | +19.8% | |
| Q4 2025 | +6.4% | +5.9% | +7.3% | |
| Q4 2024 | -3.4% | +0.0% | -1.5% | |
| Q3 2024 | +4.1% | +6.6% | -5.9% | |
| Q2 2024 | +5.6% | +1.8% | +22.7% | |
| Q1 2024 | -5.2% | -6.1% | -3.5% | |
| Q4 2023 | +9.4% | +7.8% | +28.8% | |
| Q3 2023 | +9.7% | +8.2% | +7.8% | |
| Q2 2023 | +7.4% | -3.1% | +39.9% | |
| Q1 2023 | -5.5% | -15.3% | -15.8% | |
| Q4 2022 | -4.1% | -5.6% | -11.8% | |
| Q3 2021 | +5.1% | -3.2% | -25.4% | |
| Q3 2022 | +5.4% | -3.2% | -25.4% | |
| Q2 2022 | -2.4% | -4.8% | +6.8% | |
| Q2 2021 | -3.8% | -4.8% | +6.8% | |
| Q1 2021 | +0.1% | +0.7% | -38.7% | |
| Q1 2022 | +0.0% | +0.7% | -38.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro